9:00 – 9:15 Welcome and Opening
Welcome note from the Medical Director of the Hospital Clinic
9:15 – 9:30 The BCLC Group: an Evolving Multidisciplinary Approach to Liver Cancer
Jordi Bruix, MD (Spain)
9:30 – 10:00 The Changing Epidemiology of the Disease
Massimo G. Colombo, MD (Italy)
10:00 –13:00 From Bench to Patients
Chair: Michel Beaugrand, MD (France)
10:00 – 10:30 Understanding Experimental Models
Victoria Tovar, PhD (Spain)
10:30 – 11:00 Molecular Profiling of Hepatocellular Carcinoma and Clinical Correlation
Jessica Zucman-Rossi, MD, PhD (France)
11:00 –11:30 Coffee Break
11:30 – 12:00 Dormant Malignant Cells and Avoidance of Emergence
Loreto Boix, PhD (Spain)
12:00 – 12:30 Stromal Cells and Inflammation in Cancer Progression
Peter R. Galle, MD, PhD (Germany)
12:30 – 13:00 Immunotherapy Combinations and Combining Immunotherapy Against Cancer
Ignacio Melero, PhD (Spain)
13:00 – 14:00 Lunch Break
14:00 – 18:30 Clinical Management
Chair: Josep Fuster, MD, PhD (Spain)
14:00 – 14:30 The Clinical Profiling of Patients at Diagnosis and During Evolution: the BCLC Strategy and Potential Refinement
Jordi Bruix, MD (Spain)
14:30 – 15:00 Screening for Liver Cancer: Target Population, Strategy and Cost Effectiveness
Alejandro Forner, MD (Spain)
15:00 – 15:30 Current Diagnostic and Staging Approach by Imaging
Carmen Ayuso, MD, PhD (Spain)
15:30 – 16:00 Biopsy Diagnosis and Pathology Profiling for Treatment Decision
Manel Solé, MD (Spain)
16:00 – 16:30 Surgical Resection: Feasibility vs. Effectiveness
Vincenzo Mazzaferro, MD (Italy)
16:30 – 17:00 Coffee Break
17:00 – 17:30 Liver Transplantation: Restrictive Criteria vs. Liberal Approach
Pietro Majno, MD (Switzerland)
17:30 – 18:00 Ablation as First Treatment Option for Very Early HCC
Concepció Bru, MD (Spain)
18:00 – 18:30 Prevention of Recurrence after Aiming for Cure
Josep Fuster, MD, PhD (Spain)
8:30 – 9:45 The Key Role of Radiology for Liver Cancer Management
Chair: Concepció Bru, MD (Spain)
8:30 – 9:15 Evaluation of Treatment Activity by Imaging: What Criteria Should be Used for Response Assessment and Progression Registration
Jordi Rimola, MD (Spain)
9:15 – 9:45 Transarterial Chemoembolization: Outdated Results and Current Standards
Marta Burrel, MD (Spain)
9:45 – 10:15 The Challenging Clinical Scenarios
Chair: Jordi Bruix, MD (Spain)
The Small Tumour with Nonspecific Imaging Pattern and Nondiagnostic Biopsy
Massimo G. Colombo, MD (Italy), Carmen Ayuso, MD, PhD (Spain) and Manel Solé, MD (Spain)
Treatment Decision in Patients with Very Early HCC and Fit for Resection, Transplantation and Ablation in Current Days
Josep Fuster, MD, PhD (Spain), Maria Reig, MD (Spain) and Bruno Sangro, MD, PhD (Spain)
The BCLC B Debate: Resection vs. Chemoembolization vs. Sorafenib vs. Research
Pietro Majno, Vincenzo Mazzaferro and Lluis Bianchi
10:15 – 11:00 Systemic Treatment: The Benefits of Sorafenib and the Further Understanding of the Impact in Survival
Maria Reig, MD (Spain)
11:00 – 11:15 Coffee Break
Chair: Unmet Needs and Ongoing Research
Carmen Ayuso, MD, PhD (Spain)
11:15 – 11:45 Surrogate End-Points in Cancer: the Time Dependent Analysis
Ferran Torres, MD, PhD (Spain)
11:45 – 12:15 Radioembolization for Liver Cancer: Translating Activity into Survival Benefit
Bruno Sangro, MD, PhD (Spain)
12:15 – 12:45 Molecular Profiling of Intrahepatic Cholangiocarcinoma: the Next Challenge
Josep M. Llovet, MD (Spain)
12:45 – 13:15 Systemic Treatment of Intrahepatic Cholangiocarcinoma and Novel Approaches
Josep Tabernero, MD, PhD (Spain)
13:15 Wrap Up and Farewell
Jordi Bruix, MD (Spain)